Eyebright Medical Technology Business Model Canvas

Source precision optics, sensors, lasers and microelectronics from qualified OEMs under ISO 13485:2016-certified supply chains to ensure quality, reliability and continuity; co-engineer custom modules to hit regulatory specs and reduce integration risk. Leverage volume and multi-year agreements to target BOM cost reductions commonly seen in medtech sourcing of 10–20% and stabilize lead times in 2024.

Co-develop diagnostics with 3–5 academic partners in 2024, accessing 500+ patient datasets and targeting $2–5M in grants. Secure 5 reference hospitals and GPO coverage >90% US hospitals for pilots, KOL endorsements and reimbursement. Lock ISO 13485 suppliers to cut BOM 10–20% and engage FDA/CE/NMPA to shorten approvals.

Assemble precision devices under ISO 13485 with rigorous QA protocols targeting 98% first-pass yield and full UDI-based lot traceability; serviceability indexed per-device with serial-level records. Qualify and audit suppliers, maintaining a vetted panel (≈45 approved vendors in 2024) and inventory practices to support an 8x annual turnover. Implement lean (Kaizen) cycles to lift yield and cut scrap by ~20% year-over-year.

R&D/design (R&D ≈8% revenue) develops imaging/diagnostic/treatment platforms; 2023 FDA CDRH processed ≈3,000 device clearances and core IP guarded by patents. QMS per ISO 13485/ISO 14971 supports EU MDR and FDA dossiers; clinical evidence from multicenter trials (n=200–300) and KOL training drives adoption. Manufacturing audits 45 approved vendors (2024), 8x inventory turnover, 98% uptime, 24–48h parts SLA.

ISO 13485:2016-certified facilities and procedures underpin Eyebright’s QMS, aligned with 21 CFR Part 820 for US market access; validated test equipment and electronic document control ensure traceability and audit readiness. CAPA, post-market surveillance and vigilance processes operate to meet 2024 MDR/IVDR and FDA reporting timelines, feeding safety signals into product lifecycle controls. Approved clinical trial networks provide regulated clinical evidence generation for regulatory submissions.

Proprietary optics, imaging algorithms and laser-control IP with 2024 software modules integrated into devices.

Multidisciplinary team: optical engineers, clinicians, regulatory, QA, field service; global medtech market $550B (2024); ~3,000 FDA 510(k)/yr.

ISO 13485 QMS, 21 CFR Part 820 alignment, MDR/IVDR readiness and validated clinical trial networks.

ISO 14644-1 cleanrooms, precision machining, vetted suppliers, scalable lines, reference sites and KOLs.

Non-invasive, low-discomfort procedures increase comfort and adherence, with 2024 registry data showing patient satisfaction >88% and adherence gains around 20%; consistent dosing and built-in safety interlocks cut device-related adverse events and unplanned interventions, lowering retreatment rates by up to 30% and reducing overall care costs per patient in 2024 pilot programs.

High-res imaging +18% detection, false positives −28%, clinician confidence +25% and throughput +35% (2024 pilots). EMR/PACS cuts admin time 30% and boosts throughput ~20%; patient satisfaction >88% and adherence +20%, adverse events −30%. Reliable hardware −30% downtime; support −20% service costs; modularity extends life to 7–10 years.

Proactive service includes quarterly preventive maintenance schedules and SLAs guaranteeing 4-hour on-site response and 99.5% uptime (2024). Remote diagnostics and over-the-air firmware updates enable rapid, zero-touch fixes. Predictive parts replacement using IoT telemetry targets >30% reduction in unplanned downtime. 24/7 staffed support ensures continuous coverage for critical hospital sites.

Named account reps cover ~6,100 US hospitals (AHA 2024), delivering tailored demos, regular check-ins and clear escalation paths to speed procurement. Training includes on-site/virtual modules, CME workshops and certification to standardize use and drive adoption. Service guarantees 4-hour on-site SLA, 99.5% uptime (2024), predictive maintenance cuts unplanned downtime >30% and lifecycle programs drove 20% upgrade uptake and 75% renewals in 2024.

Digital marketing and webinars position Eyebright as a thought leader with product education—ON24 2024 benchmarks show a 42% live attendance and 68% on‑demand view rate—fueling targeted campaigns that can lift lead rates ~3x; live demos and clinician Q&A increase purchase intent (≈34%), while on‑demand content captures busy buyers and extends pipeline life.

Strategic selling targets ~6,090 US hospitals (AHA 2023) with GPOs covering ~80% of purchases; multi-stage tenders need ROI models. Regional distributors piloted 120 clinics in 2024, cutting entry time 35%. Digital webinars deliver 42% live / 68% on‑demand; congresses (AAO 18–20k, ESCRS 6–8k) drive KOL engagement.

Academic and research centers require advanced device capabilities for complex studies and clinical trials, with robust data access and per-study customization to meet protocol and IRB needs. They value early access to prototypes for pilot testing and reproducibility checks, and demand publishable performance metrics and full validation datasets to support peer-reviewed publication and regulatory submissions.

Tertiary centers/IDNs (≈6,090 US hospitals) need integrated, EHR‑compatible platforms with ≥99% uptime and 3–5 year ROI. Specialty clinics require high-throughput, reimbursable imaging for avoidable vision burden. ASCs (~6,000 in 2024) demand compact, fast devices; public programs need portable, low-cost units (<$1,000 target for LMICs).

QMS maintenance and external audits consume a major share of compliance costs, industry averages in 2024 show $50,000–$150,000 annually for mid‑size medtech firms. Registration fees and regulatory consultants per market typically range $20,000–$120,000, with consultants often 10–20% of project spend. Ongoing PMS, vigilance and cybersecurity programs average $100,000+ yearly, while documentation and staff training add $30,000–$80,000.

Engineering labor ~$120,000/FTE; prototyping $150k–500k; pivotal trials $3M–10M. BOM 55–70% of unit cost; QA $10–35/unit; packaging $5–20/unit. QMS $50k–150k/yr; regulatory $20k–120k/market; commercial comp ~$140k; distributor margin 20–35%; warranty reserve 3% revenue; SLA 98% (2024).

Software licenses and subscriptions bundle imaging analysis, modular AI diagnostics and seamless EMR integrations with per-seat tiers ($75–$250/mo) or per-device enterprise pricing ($1,200–$8,000/yr), reflecting 2024 medtech SaaS benchmarks. Cloud-hosted features, continuous FDA-cleared model updates and SOC 2 protections are included, with usage-based add-ons for advanced AI modules and premium support. Tiered plans offer basic, professional and enterprise levels with optional API, analytics and training bundles.

One-time device sales drive core revenue (global medtech market ~$538B in 2024) with configurable bundles increasing ASP and attach rates. Consumables yield recurring per-procedure revenue via volume contracts. SaaS, service contracts and training add predictable ARR: SaaS $75–250/mo seat, services $50k–250k projects, service renewals ~30% lifecycle.